

# Overview of the Nutrition in CKD Guidelines

## Slides

Nutrition in CKD Guideline Update  
Part 1: Overview

WHAT IS NEW AND WHAT DO WE CHANGE?

1

### Agenda

- Introduction – Alp Ikizler, MD
- Guideline Development Process – Alison Steiber, PhD, RDN
- What is Different in the Updated Guideline? – Alp Ikizler, MD
- Conclusion – Alp Ikizler, MD

2

### Objectives

- Explain the guideline development process and the benefits of multidisciplinary collaboration between the National Kidney Foundation and the Academy of Nutrition and Dietetics to produce global evidence-based nutrition guidelines for patients with chronic kidney disease.
- Recognized the differences between the KDOQI Nutrition 2000 and KDOQI Nutrition 2020 recommendations.

3

### Faculty Disclosures


T. Alp Ikizler, MD  
Consultant and received honoraria for his consulting work from Abbott Renal Care, Fresenius Kabi, Nestle, and Reata.

Alison Steiber, PhD, RDN  
Employed by the Academy of Nutrition and Dietetics; grants from Anjinomoto, Relypsa, American Council on Exercise, Commission on Dietetic Registration; socks in Nephroceuticals, Inc.

4

### Introduction

5



6

# Overview of the Nutrition in CKD Guidelines

## Slides

Clinical Practice Guidelines for Nutrition in Chronic Renal Failure

**NKF** National Kidney Foundation  
**AJKD** American Journal of Kidney Diseases  
 VOL 35, NO 6, SUPPL 2, JUNE 2000

- ✓ Published in 2000
- ✓ Content and relevance changed
- ✓ Not graded

7

International representation of Work Group Members

8

NKF-KDOQI and Academy-EAL collaboration on CKD Guideline Work Group Members

Co-Chairs: T. Alp Iktizler, MD & Lillian Cuppari, PhD

**Macronutrients**  
 Laura Byham-Gray, PhD, RDN, FNKF (Chair)  
 Denis Fouque, MD, PhD  
 Winnie Chan, PhD, RD  
 Jerrilynn Burrows, PhD, RD, CDN  
 Daniel Teta, MD, PhD

**Micronutrients**  
 Angela Wang, MD, PhD (Chair)  
 Jordi Fuchs, DSc, APN, NP-C, RD  
 Joel Kopple, MD  
 Sana Ghadiri, PhD, RDN  
 Alp Iktizler, MD

**Electrolytes & other nutrients**  
 Juan Jesus Carrero, PhD Pharm, PhD Med, MBA (Chair)  
 Katrina Campbell, PhD, RD  
 George Kaysen, MD, PhD  
 Allison Friedman, MD, FASN  
 Lillian Cuppari, PhD


NATIONAL KIDNEY FOUNDATION | eat right Academy of Nutrition and Dietetics

9


Guideline Development Process

NATIONAL KIDNEY FOUNDATION | eat right Academy of Nutrition and Dietetics

10



11



12

# Overview of the Nutrition in CKD Guidelines

## Slides

### Question Development : PICO format

- Questions are organized by subtopics and within subtopics by Nutrition care process:
  - Macronutrients
  - Micronutrients
  - Electrolytes
- Overview of questions within subtopics are focused on:
  - Assessment questions
  - Intervention questions
  - Monitoring questions

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

13

### Outcomes of Interest (not all are presented here)

Major categories of outcomes:

- Hard outcomes: Mortality, RRT, QoL etc hospitalizations
- Nutritional status outcomes: SGA, PWS, Protein markers etc
- Dietary intake outcomes: FFQ, 24-hr recall, diet history etc
- Inflammation outcomes: CRP, adipokines, cytokines etc
- Anthropometrics: Body wt, BMI, WC, Skinfold thickness etc

- Major categories of outcomes:
  - Electrolyte biomarkers:
    - Na, Mg, K, Phos, Ca, Acid load etc
  - Micronutrient biomarkers:
    - Serum or urinary excretion for all included micronutrient
  - CKD progression:
    - eGFR, s. creatinine, etc
  - Comorbidity outcomes
    - Lipid profile, BP etc

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

14

### Gather and Classify the Research : Search Process – A Rigorous Process

Workgroup Oversees/Decision Makers

**Develop search plan:** Inclusion and exclusion criteria

**Conduct search:** Appropriate search & MeSH terms; Multiple databases

**Determine inclusion/exclusion articles:** Review abstracts & articles; Rationale for excluding articles

**Document:** PRISMA format for documentation is used

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

15

### Search Plan

- Brief Inclusion criteria
  - CKD all stages
  - Searched databases from 1985 to 2016
  - Limited to controlled trials for intervention questions
    - At least n=6 in each arm
  - Limited to controlled trials + observational studies for assessment questions
  - Assessment questions: studies needed to have a comparative tool/method
  - Searched multiple databases
  - Hand searched published Systematic reviews and other guidelines

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

16

### Search Results

Search for literature related to Intervention questions completed

Comprehensive search of databases: 10,974 citations

43 citations from other sources

11,017 Citations Screened

1,902 Excluded after 1st Review of titles and abstracts & duplicates removed

1097 abstracts meet criteria and are included

296 excluded after abstract review

303 full text articles reviewed

520 excluded after full text review

281 Included in Systematic Review

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

18

### Critically Appraise Each Article and data extraction: Risk of bias

- Academy of Nutrition and Dietetics Quality criteria checklist (QCC) was used
  - QCC is based on ROB domains of Cochrane
- Data extraction
  - Data extraction guide based on questions that needed to be answered was developed
  - Used Academy's online data extraction tool (DET)
- Read and analyze articles
  - Complete worksheets (DET for each article)
  - Complete quality checklists

NATIONAL KIDNEY FOUNDATION | Academy of Nutrition and Dietetics

19

# Overview of the Nutrition in CKD Guidelines

## Slides

### Double Blind Bias Assessment

Assessment of bias by two analysts, blinded to each others answers.

Disagreements identified and consensus reached

NATIONAL KIDNEY FOUNDATION Academy of Nutrition, Dietetics and Therapeutics

20

### Summarize the Evidence: Aggregating the data

Article 1

Article 2

Article 3

Evidence Summary Table

Conclusion statement

22

### Evidence Statements and Study Details for each Outcome

**Conclusion Statement**  
 CKD progression (Predictor: dietary phosphate restriction): In pre-dialysis patients, dietary protein and phosphate restriction did not slow the rate of CKD progression (e.g., mean rate of fall of creatinine clearance, plasma creatinine, or distribution of those who improved or worsened) in one study.  
 Proposed Grade for Quality of Evidence: B

**Evidence Summary**  
 In pre-dialysis patients, the effects of dietary phosphate restriction and phosphorus/phosphate biomarkers on CKD progression were mixed and also evidence was limited (three studies). Compared to control, dietary protein and phosphate restriction and phosphate restriction only did not show any significant difference in mean rate of fall of creatinine clearance, plasma creatinine, or distribution of those who improved, worsened or were unchanged (Williams et al, 1991; dietary protein and phosphate restriction; protein: 0.6 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day; dietary phosphate restriction only: protein: 0.8 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day (plus orally administered phosphate binder)). Greater 24-hr urinary phosphate excretion was not associated with ESRD (i.e., progressed to ESRD) in Selamet et al, 2016, while greater urinary phosphorus excretion per creatinine clearance was associated with greater CKD progression (e.g., progressed to ESRD or 50% reduction of eGFR) in Kawasaki et al, 2015. In adults with chronic kidney disease, one positive-quality randomized controlled trial (Williams et al, 1991), one positive-quality prospective cohort study (Selamet et al, 2016), and one positive-quality retrospective cohort study examined the effects of dietary phosphate intake or phosphorus/phosphate biomarkers on CKD progression.

Phos = phosphorus

24

### Results from SR = Evidence Summary Table

Study	Sample Characteristics	Intervention/Duration	Outcomes	Relative risk and confidence		Study Quality
				RR (95% CI)	CG (95% CI)	
Dietary intake						
Williams 1991	N = 93 European (88) Randomized Controlled Trial	Dietary protein and phosphate restriction: Protein: 0.6 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day	Dietary protein and phosphate restriction: Protein: 0.8 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day	Control: 329% (10.7%)	339% (10.7%)	+
Phos (Phosphate)						
		Dietary phosphate restriction only: Protein: 0.8 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day (plus orally administered phosphate binder)	Dietary phosphate restriction only: Protein: 0.6 g/kg/day, phosphate: 800 mg, energy intake ≥ 30 kcal/kg/day (plus orally administered phosphate binder)	Control: 348% (11.5%)	348% (11.5%)	
		Control: Protein: 0.8 g/kg/day, energy intake ≥ 30		308% (7)		

25

### GRADE Table: Phosphorus/Phosphate

Ref of article	Study Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	No of patients		Effect	Quality	Implications
							phosphorus/phosphate restriction	control			
Dietary phosphorus/phosphate restriction (Williams et al, 1991; Liu et al, 2010; Selamet et al range 10 months to 19 months)											
2	randomized trial	low	none	none	none	none	108	108	HR 0.84 (95% CI 0.53-1.35)	MODERATE	HRB IMPROVING
Phosphorus/phosphate restriction (Williams et al, 1991; Selamet et al, 2016; Liu et al, 2010; Selamet 2016; Selamet et al range 10 months to 19 months)											
1	randomized trial	low	none	none	none	none	207	207	HR 0.84 (95% CI 0.53-1.35)	MODERATE	HRB IMPROVING

26

### SR to Practice Recommendations

Article data

Systematic Reviews

EBP Nutrition Guidelines

Recommendation statements

28

# Overview of the Nutrition in CKD Guidelines

## Slides

### GRADE Methodology

Assigns separate grades for:

- 1) **Evidence Quality**
- 2) **Strength of Recommendation**

Quality of evidence	High	A	Strength of recommendation	Level 1
	Moderate	B		
	Low	C		Level 2
	Very low	D		

Guideline work group decision

30

### Limitations and issues

Literature search was intended to be comprehensive, however, they were not exhaustive.

Were not able to contact authors for incomplete data. Data presented in published original research was used in data analysis.

Eligible studies published after search dates or in congress proceedings have not been included.

Inconsistent reporting of clinical outcomes of interest resulted in evidence synthesis difficulty. (standardization of outcomes is needed in this field)

Low quality evidence in certain areas required substantial use of WG expertise to draft a recommendation

Issues with nutrition studies: baseline exposure, nutrient status, confounding variables...

33

## What is Different in the Updated Guideline?

34

### What is different in the Updated Guidelines?

<p><b>KDOQI 2000 guideline</b></p> <ul style="list-style-type: none"> <li>• Population: Maintenance Dialysis; Adv. CRF without Dialysis</li> <li>• Literature search dates: 1966 – 1997</li> </ul>	<p><b>Update KDOQI-Academy of Nutrition and Dietetics guideline</b></p> <ul style="list-style-type: none"> <li>• Population: Adults with Chronic Kidney Disease: Stages 1-5, including dialysis and post-kidney transplant</li> <li>• Literature search dates: 1985 - 2016</li> </ul>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

35

### What is different in the Updated Guidelines?

<ul style="list-style-type: none"> <li>• Topic covered             <ul style="list-style-type: none"> <li>• Evaluation of Protein Energy Nutritional Status</li> </ul> </li> <li>• Management of Acid-Base Status and Protein and Energy Status</li> <li>• Nutritional Counseling and Follow-up</li> <li>• Carnitine</li> </ul>	<ul style="list-style-type: none"> <li>• Topics covered             <ul style="list-style-type: none"> <li>• More Comprehensively covered and additional "NEW" statements; more evidence-based statements</li> <li>• Carnitine- literature in this area was NOT explored in this update</li> <li>• Micronutrients- NEW</li> <li>• Electrolytes-NEW</li> </ul> </li> </ul>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

36

## Assessment Recommendations

- Composite Nutrition Assessment Scores
  - Dietary Intake Assessment
  - Resting Energy Expenditure
    - Laboratory Values
- Anthropometric and other measures to assess body composition
- Technical Devices to assess body composition

37

## Slides

Assessment Recommendations		
KDOQI (2000)	KDOQI-AND (2019)	Changes
No specific screening recommendation	<b>Routine Nutrition Screening</b> ✓ In adults with <b>CKD 3-5D and post-transplant</b> , it is reasonable to consider routine nutrition screening at least biannually with the intent of identifying those at risk of protein-energy wasting (OPINION).	New
N/A	<b>Nutrition Screening Tools</b> ✓ In adults with <b>CKD 3-5D and post-transplant</b> , there is limited evidence to suggest the use of one tool over others for identifying those at risk of protein-energy wasting (2D).	New

38

Assessment Recommendations - Body Composition		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<b>Dual Energy X-Ray Absorptiometry (DXA)</b> • DXA is a valid and clinically useful technique for assessing protein energy nutritional status. (Evidence and Opinion) • Accurate data on body composition are helpful to assess long-term adequacy of protein-energy nutritional status. • Whole body DXA provides an accurate method to assess body composition which is less influenced by the abnormalities in hydration status common in maintenance dialysis patients.	<b>DEXA for Body Composition Assessment</b> • In adults with <b>CKD 3-5D and post-transplant</b> , it is reasonable to use dual-energy x-ray absorptiometry (DEXA) when feasible as it remains the <b>gold standard</b> for measuring body composition despite being influenced by volume status (OPINION).	Updated: Included non-ESRD

39

Assessment Recommendations - Serum Biomarkers		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<b>Serum Albumin</b> • Serum albumin is a valid and clinically useful measure of protein-energy nutritional status in maintenance dialysis (MD) patients. (Evidence)	<b>Serum Albumin Levels</b> • In adults with <b>CKD on maintenance dialysis</b> , low serum albumin may be used as a predictor of <b>hospitalization and mortality (1A)</b> .	Updated
<b>Serum Prealbumin</b> <b>Serum Cholesterol</b> <b>Serum Creatinine</b> • Serum Prealbumin, Cholesterol and Creatinine are valid and clinically useful markers of protein-energy nutritional status in maintenance hemodialysis patients. (Evidence and Opinion)	<b>No specific statement</b> Covered under Rationale Section	Updated

40

Assessment Recommendations - SGA/MIS		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<b>Subjective Global Nutritional Assessment (SGA)</b> • SGA is a valid and clinically useful measure of protein-energy nutritional status in maintenance dialysis patients. (Evidence)	<b>7-point Subjective Global Assessment (SGA)</b> • In adults with <b>CKD 5D</b> , we recommend the use of the 7-point Subjective Global Assessment as a <b>valid and reliable tool</b> for assessing nutritional status (1B).	Updated
N/A	<b>Malnutrition Inflammation Score (MIS)</b> • In adults with <b>CKD on MHD and post-transplant</b> , Malnutrition Inflammation Score may be used to assess nutritional status (2C).	New

41

Assessment Recommendations - Nutrient Intake		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<b>Dietary Interviews and Diaries</b> • Dietary interviews and/or diaries are valid and clinically useful for measuring dietary protein and dietary energy intake in maintenance dialysis patients. (Evidence and Opinion)	<b>Considerations when Assessing Dietary Intake</b> • In adults with <b>CKD 3-5D and post-transplant</b> , it is reasonable to assess factors beyond dietary intake (e.g. medication use, knowledge, beliefs, attitudes, behavior and access to food, depression, cognitive function etc.) to effectively plan nutrition interventions. (OPINION).  <b>3 Day Food Records to Assess Dietary Intake</b> • In adults with <b>CKD 3-5D</b> , we suggest the use of a <b>3-day food record</b> , conducted during both dialysis and non-dialysis treatment days (when applicable), as a preferred method to assess dietary intake (2C).	Updated; New Statements

42

Intervention Recommendations
- Medical Nutrition Therapy (MNT) - Protein requirements - Energy requirements - Protein-Energy supplements (oral, dialysate, IDPN, enteral & parenteral) - omega-3 supplements - Dietary Patterns - Micronutrients - Electrolytes

43

# Overview of the Nutrition in CKD Guidelines

## Slides

Intervention Recommendations - MNT		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Intensive Nutritional Counseling With Maintenance Dialysis (MD)</b></p> <ul style="list-style-type: none"> <li>Every MD patient should receive intensive nutritional counseling based on an individualized plan of care developed before or at the time of commencement of MD therapy. (Opinion).</li> <li>A plan of care for nutritional management should be developed before or during the early phase of MD care and modified frequently based on the patient's medical and social conditions.</li> <li>The plan of care should be updated at least every 3 to 4 months.</li> <li>Nutrition counseling should be intensive initially and provided thereafter every 1 or 2 months and more frequently if adequate nutrient intake or malnutrition is present or if adverse events or illnesses occur that may cause deterioration in nutritional status.</li> </ul>	<p><b>Medical Nutrition Therapy</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5D, we recommend that a registered dietitian nutritionist (RDN) or an international equivalent, in close collaboration with a physician or other provider (nurse practitioner or physician assistant), provide medical nutrition therapy (MNT). Goals are to optimize nutritional status, and to minimize risks imposed by comorbidities and alterations in metabolism on the progression of kidney disease (1C) and on adverse clinical outcomes. (OPINION).</li> <li>MNT should be tailored to the individuals' needs, nutritional status, and comorbid conditions. (OPINION).</li> </ul>	Updated

44

Intervention Recommendations - DPI_CKD		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Dietary Protein Intake for Nondialysis Patients</b></p> <ul style="list-style-type: none"> <li>For individuals with chronic renal failure (GFR <math>\leq</math> 25 mL/min) who are not undergoing maintenance dialysis, the institution of a planned low-protein diet providing 0.60 g protein/kg/d should be considered.</li> <li>For individuals who will not accept such a diet or who are unable to maintain adequate DEI with such a diet, an intake of up to 0.75 g protein/kg/d may be prescribed. (Evidence and Opinion)</li> </ul>	<p><b>Protein Restriction, Non-Dialysis</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5 who are metabolically stable, we recommend protein restriction with or without keto acid analogs, depending on keto analog availability, patient preference and clinician judgement, to reduce risk for ESRD/death (1A) and improve QoL (2C).</li> <li>a low protein diet providing 0.55 to 0.60 g dietary protein per kg body weight per day, OR</li> <li>a very-low protein diet providing 0.28 to 0.43 g dietary protein/kg body weight/day with additional keto acid analogs to meet protein requirements (0.55 to 0.60 g/kg body weight/day)</li> </ul>	Updated Strong Imperative

45

Intervention Recommendations - DPI_CKD		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Dietary Protein Intake for Nondialysis Patients - DM</b></p> <p>N/A</p>	<p><b>Protein Restriction, Non-Dialysis - DM</b></p> <ul style="list-style-type: none"> <li>In the adult with CKD 3-5 (non-dialyzed) and who have diabetes, it is reasonable to prescribe a dietary protein intake of 0.6-0.8 g/kg body weight per day to maintain a stable nutritional status and optimize glycemic control. (Opinion)</li> </ul>	NEW Opinion
<p><b>Protein Intake During Acute Illness</b></p> <ul style="list-style-type: none"> <li>The optimum protein intake for a maintenance dialysis patient who is acutely ill is at least 1.2 to 1.3 g/kg/d. (Opinion)</li> <li>Acutely ill maintenance hemodialysis patients should receive at least 1.2 g protein/kg/d.</li> <li>Acutely ill chronic peritoneal dialysis patients should receive at least 1.3 g protein/kg/d.</li> </ul>	<p>N/A</p>	

46

Intervention Recommendations - DPI_MHD		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Dietary Protein Intake (DPI) in Maintenance Hemodialysis (MHD)</b></p> <ul style="list-style-type: none"> <li>The recommended DPI for clinically stable MHD patients is 1.2 g/kg body weight/d. (Evidence and Opinion)</li> <li>At least 50% of the dietary protein should be of high biological value.</li> </ul>	<p><b>Dietary Protein Intake, Maintenance Hemodialysis and Peritoneal Dialysis</b></p> <ul style="list-style-type: none"> <li>In adult with CKD on MHD (1C) and PD (OPINION) who are metabolically stable, we recommend prescribing a dietary protein intake of 1.0-1.2 g/kg ideal body weight per day to maintain a stable nutritional status.</li> </ul>	Updated
<p><b>Dietary Protein Intake, MHD/PD; DM</b></p> <p>N/A</p>	<p><b>Dietary Protein Intake, MHD/PD; DM</b></p> <ul style="list-style-type: none"> <li>In adults with CKD on MHD and PD and who have diabetes, it is reasonable to prescribe a dietary protein intake of 1.0-1.2 g/kg body weight per day to maintain a stable nutritional status. For patients at risk of hyper and/or hypoglycemia, higher levels of dietary protein intake may need to be considered to maintain glycemic control. (OPINION).</li> </ul>	New

47

Intervention Recommendations - DPI_PD		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Dietary Protein Intake (DPI) for Chronic Peritoneal Dialysis (CPD)</b></p> <ul style="list-style-type: none"> <li>The recommended DPI for clinically stable CPD patients is 1.2 to 1.3 g/kg body weight/d. (Evidence)</li> <li>Dietary protein intake should be no less than 1.2 g/kg/d.</li> <li>Unless a patient has demonstrated adequate protein nutritional status on a 1.2 g protein/kg/d diet, 1.3 g protein/kg/d should be prescribed.</li> <li>At least 50% of the dietary protein should be of high biological value.</li> </ul>	<p><b>Dietary Protein Intake, Maintenance Hemodialysis and Peritoneal Dialysis</b></p> <ul style="list-style-type: none"> <li>In adult with CKD on MHD (1C) and PD (OPINION) who are metabolically stable, we recommend prescribing a dietary protein intake of 1.0-1.2 g/kg ideal body weight per day to maintain a stable nutritional status.</li> </ul>	Updated

48

Intervention Recommendations - Protein type		
KDOQI (2000)	KDOQI-AND (2019)	Changes
N/A	<p><b>Protein Type</b></p> <p>In adults with CKD 1-5D (1B) and post-transplant (OPINION), there is insufficient evidence to make conclusions about the effects of protein type (plant vs animal) on nutritional status, calcium or phosphorus levels, or the blood lipid profile.</p>	New Opinion

49

# Overview of the Nutrition in CKD Guidelines

## Slides

Intervention Recommendations - Energy_CKD/MD		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Dietary Energy Intake (DEI) for Nondialyzed and Maintenance Dialysis Patients</b></p> <ul style="list-style-type: none"> <li>The recommended DEI for individuals with chronic renal failure (CRF; GFR <math>\geq 25</math> mL/min) who are not undergoing maintenance dialysis is <b>35 kcal/kg/d</b> for those who are younger than 60 years old and 30 to 35 kcal/kg/d for individuals who are 60 years of age or older. (Evidence and Opinion)</li> <li>The recommended daily energy intake for maintenance hemodialysis or chronic peritoneal dialysis patients is <b>35 kcal/kg body weight/d</b> for those who are less than 60 years of age and 30 to 35 kcal/kg body weight/d for individuals 60 years or older. (Evidence and Opinion)</li> </ul>	<p><b>Energy, CKD 1-5D and post-Tx</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5D (1C) and post-transplant (OPINION) who are metabolically stable, we recommend prescribing an energy intake of <b>25-35 kcal/kg ideal body weight per day</b> based on age, gender, level of physical activity, body composition, weight status goals, CKD stage, and concurrent illness or presence of inflammation to maintain normal nutritional status.</li> </ul>	Updated Opinion

50

Dietary Protein and Energy Intake Implementation considerations	
<ul style="list-style-type: none"> <li>Increase the training and number of specialized renal dietitians worldwide.</li> <li>Gradual implementation is more likely to succeed.</li> <li>Enforce the dietary interventions to improve symptoms when chronic dialysis is not a treatment option or is to be postponed (vascular access maturation, organizing pre-emptive renal transplant, ..)</li> <li>If wasting is present, priority should be given to the correction of wasting.</li> <li>Compliance to diets should be monitored frequently during the first year of dietary intervention by dietary interviews (3 are optimal) and urine collection for urea output measures.</li> <li>Then yearly follow-up recommended until start of maintenance dialysis.</li> </ul>	<p>NATIONAL KIDNEY FOUNDATION</p> <p>Academy of Nutrition and Dietetics</p> <p>51</p>

51

Intervention Recommendations - Nutritional Supplementation		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Indications for Nutritional Support</b></p> <p>Individuals undergoing maintenance dialysis who are unable to meet their protein and energy requirements with fluid intake for an extended period of time should receive nutritional support. (Evidence and Opinion)</p> <ul style="list-style-type: none"> <li>The period of inadequate intake after which nutritional support should be initiated ranges from 2 to 6 weeks, depending on the severity of the patient's clinical condition, degree of malnutrition (if any), and the degree of instability of their nutritional status.</li> <li>Before considering nutrition support, the patient should receive a complete nutritional assessment.</li> <li>It may potentially be reversible or treatable condition or medications that might interfere with aspects of these interventions should be discontinued or treated.</li> <li>If oral nutrition support (ie oral diet) may be fortified with energy and protein supplements.</li> <li>If oral nutrition (including nutritional supplementation) is inadequate, tube feeding should be offered if clinically appropriate.</li> <li>If tube feeding is not used, intradialytic parenteral nutrition (IDPN) for hemodialysis or intraperitoneal parenteral nutrition (IPN) for peritoneal dialysis should be considered if other approaches to nutrition with wasting and/or intake meet the protein and energy requirements.</li> <li>If the combination of oral intake and IDPN or IPN does not meet protein and energy requirements, daily total or partial parenteral nutrition should be considered.</li> <li>The dietary regimen should be regularly monitored and modified to meet any modification of the patient's uremic state that is caused by superimposed illness or increased protein intake.</li> </ul>	<p><b>Oral Protein-Energy Supplementation</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D (2D) and post-transplant (OPINION) at risk of or with protein-energy wasting, we suggest a minimum of a 3-month trial of oral nutritional supplements to improve nutritional status if dietary counselling alone does not achieve sufficient energy and protein intake to meet nutritional requirements.</li> </ul>	Updated

52

Specifics of Oral Nutritional Supplementation	
Who	All versus at-risk
When	During Dialysis; In between meals
How much	Replacement versus Supplementation
How long	> 3-months
How to monitor	Weight Biomarkers

NATIONAL KIDNEY FOUNDATION Academy of Nutrition and Dietetics 53

53

Intervention Recommendations - Nutritional Supplementation		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Indications for Nutritional Support</b></p> <p>Individuals undergoing maintenance dialysis who are unable to meet their protein and energy requirements with fluid intake for an extended period of time should receive nutritional support. (Evidence and Opinion)</p> <ul style="list-style-type: none"> <li>The period of inadequate intake after which nutritional support should be initiated ranges from 2 to 6 weeks, depending on the severity of the patient's clinical condition, degree of malnutrition (if any), and the degree of instability of their nutritional status.</li> <li>Before considering nutrition support, the patient should receive a complete nutritional assessment.</li> <li>It may potentially be reversible or treatable condition or medications that might interfere with aspects of these interventions should be discontinued or treated.</li> <li>If oral nutrition support (ie oral diet) may be fortified with energy and protein supplements.</li> <li>If oral nutrition (including nutritional supplementation) is inadequate, tube feeding should be offered if clinically appropriate.</li> <li>If tube feeding is not used, intradialytic parenteral nutrition (IDPN) for hemodialysis or intraperitoneal parenteral nutrition (IPN) for peritoneal dialysis should be considered if other approaches to nutrition with wasting and/or intake meet the protein and energy requirements.</li> <li>If the combination of oral intake and IDPN or IPN does not meet protein and energy requirements, daily total or partial parenteral nutrition should be considered.</li> <li>The dietary regimen should be regularly monitored and modified to meet any modification of the patient's uremic state that is caused by superimposed illness or increased protein intake.</li> </ul>	<p><b>Enteral and Parenteral Nutrition supplementation</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5D, with chronically inadequate intake and whose protein and energy requirements cannot be attained by dietary counselling, oral nutritional supplements and/or IDPN should be considered for enteral tube feeding or total parenteral nutrition (OPINION).</li> </ul>	Updated

54

Intervention Recommendations - Nutritional Supplementation		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Indications for Nutritional Support</b></p> <p>Individuals undergoing maintenance dialysis who are unable to meet their protein and energy requirements with fluid intake for an extended period of time should receive nutritional support. (Evidence and Opinion)</p> <ul style="list-style-type: none"> <li>The period of inadequate intake after which nutritional support should be initiated ranges from 2 to 6 weeks, depending on the severity of the patient's clinical condition, degree of malnutrition (if any), and the degree of instability of their nutritional status.</li> <li>Before considering nutrition support, the patient should receive a complete nutritional assessment.</li> <li>It may potentially be reversible or treatable condition or medications that might interfere with aspects of these interventions should be discontinued or treated.</li> <li>If oral nutrition support (ie oral diet) may be fortified with energy and protein supplements.</li> <li>If oral nutrition (including nutritional supplementation) is inadequate, tube feeding should be offered if clinically appropriate.</li> <li>If tube feeding is not used, intradialytic parenteral nutrition (IDPN) for hemodialysis or intraperitoneal parenteral nutrition (IPN) for peritoneal dialysis should be considered if other approaches to nutrition with wasting and/or intake meet the protein and energy requirements.</li> <li>If the combination of oral intake and IDPN or IPN does not meet protein and energy requirements, daily total or partial parenteral nutrition should be considered.</li> <li>The dietary regimen should be regularly monitored and modified to meet any modification of the patient's uremic state that is caused by superimposed illness or increased protein intake.</li> </ul>	<p><b>Intradialytic Parenteral Nutrition (IDPN) Protein-Energy Supplementation</b></p> <ul style="list-style-type: none"> <li>In adults with CKD with protein-energy wasting, we suggest a trial of TPN for CKD 1-5 patients (2C) and IDPN for CKD 5D on MHD patients (2C), to improve and maintain nutritional status if nutritional requirements cannot be met with existing oral and enteral intake.</li> </ul>	Updated


55

# Overview of the Nutrition in CKD Guidelines

## Slides

Intervention Recommendations - Nutritional Supplementation		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Indications for Nutritional Support</b></p> <p>Individuals undergoing maintenance dialysis who are unable to meet their protein and energy requirements with high intake for an extended period of time should receive nutritional support. (Evidence and Grades)</p> <ul style="list-style-type: none"> <li>The goal of nutritional intake after which nutritional support should be initiated ranges from after 1-2 weeks, depending on the severity of the patient's clinical condition, degree of malnutrition, and whether degree of malnutrition is reversible.</li> <li>When initiating nutritional support, the patient should receive a complete nutritional intervention.</li> <li>It is generally reasonable or reasonable to consider an individual's nutritional status with respect to lower malnutrition should be addressed or treated.</li> <li>The nutritional support that is best suited to the patient's goals, energy and protein requirements.</li> <li>Oral and enteral (including nutritional supplementation) interventions, when feasible, should be preferred to intravenous approaches.</li> <li>If later findings are not used, intradialytic parenteral nutrition (IDPN) for hemodialysis or postdialytic parenteral nutrition (PDN) for peritoneal dialysis should be considered if other approaches are ineffective with timing and intake meet therapeutic and energy requirements.</li> <li>The combination of oral intake and IDPN or PDN does not meet protein and energy requirements, and oral or parenteral nutrition should be considered.</li> <li>The dialysis regimen should be regularly monitored and modified to meet any modification of the patient's specific goals related to appropriate clinical or personal protein intake.</li> </ul>	<p><b>Dialysate Protein-Energy Supplementation</b></p> <ul style="list-style-type: none"> <li>In adults with CKD on peritoneal dialysis with protein-energy wasting, we suggest <u>not substituting</u> conventional dextrose dialysate with amino acid dialysate as a general strategy to improve nutritional status (2C), although in selected cases of protein-wasting when energy intake is adequate, 1.1% amino acid dialysate with alkali supplements may ameliorate protein deficits (OPINION).</li> </ul>	Updated

56



57

Intervention Recommendations - LC n-3 PUFA		
KDOQI (2000)	KDOQI-AND (2019)	Changes
N/A	<p><b>LC n-3 PUFA Nutritional Supplements for Lipids, Mortality and CVD</b></p> <ul style="list-style-type: none"> <li>In adults with CKD on MHD, PD (Opinion) or post-transplant, we suggest not routinely prescribing long-chain n-3 PUFA, including those derived from fish or flaxseed and other oils, to lower risk of mortality (2C) or cardiovascular events (2B).</li> <li>In adults with CKD on MHD, we suggest that 1.3-4 g/d long-chain n-3 PUFA may be prescribed to reduce triglycerides and LDL cholesterol (2C) and raise HDL levels (2D).</li> <li>In adults with CKD on PD, it is reasonable to consider prescribing 1.3-4 g/d long-chain n-3 PUFA to improve the lipid profile (OPINION).</li> </ul>	New

58

Intervention Recommendations - LC n-3 PUFA		
KDOQI (2000)	KDOQI-AND (2019)	Changes
N/A	<p><b>LC n-3 PUFA Nutritional Supplements for AV Graft and Fistula Patency</b></p> <ul style="list-style-type: none"> <li>In adults with CKD on MHD, we suggest not routinely prescribing fish oil to improve primary patency rates in patients with AV grafts (2B) or fistulas (2A).</li> </ul> <p><b>LC n-3 PUFA Nutritional Supplements for Kidney Allograft Survival</b></p> <ul style="list-style-type: none"> <li>In adults with CKD with kidney allograft, we suggest not routinely prescribing long-chain n-3 PUFA to reduce the number of rejection episodes or improve graft survival (2D).</li> </ul>	New

59

Intervention Recommendations - Dietary Patterns		
KDOQI (2000)	KDOQI-AND (2019)	Changes
<p><b>Mediterranean Diet</b></p> <p>N/A</p>	<p><b>Mediterranean Diet</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5 (non-dialysis) and post-transplant, with or without dyslipidemia, we suggest that prescribing a Mediterranean Diet may improve lipid profiles (2C).</li> </ul>	New Weak, Conditional
<p><b>Fruits and Vegetables</b></p> <p>N/A</p>	<p><b>Fruits and Vegetables</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-4, we suggest that prescribing increased fruit and vegetable intake may decrease body weight, blood pressure and net acid production (NEAP) (2C).</li> </ul>	New Weak, Conditional

60

**Generalities: Vitamins and Trace-Elements**

Ideal amounts of daily vitamins and trace elements are those required to:

- Maintain health / prevent diseases
- Maintain nutritional status
- Reverse deficiencies
- Prevent toxicity

Recommendations for vitamins/trace element intakes are challenging

- Depend on physical properties (hydro vs fat-solubility)
- Depend on type of population: General population vs CKD patients
- Depend on body stores, previous supplementation, nutritional status and intake, Gut absorption, impaired renal metabolism, additional losses through dialysis

61

# Overview of the Nutrition in CKD Guidelines

## Slides

Recommended Dietary Allowances for Adult General Population

Micronutrients	Recommended Dietary Allowance (per day)
Thiamin	1.2mg (M), 1.1mg (F)
Vitamin B12	2.4µg (M & F)
Folic acid	400 µg (M & F)
Vitamin C	90mg (M), 75mg (F)
Vitamin D	10 µg (M), 5 µg (F)
Vitamin E	15mg (M & F)
Vitamin K	120 µg (M), 90 µg (F)
Selenium	55 µg (M & F)
Zinc	11mg (M), 8 mg (F)

NATIONAL KIDNEY FOUNDATION 62

62

Intervention Recommendations - Vitamins

KDOQI (2000)	KDOQI-AND (2019)	Changes
Folic Acid and B vitamins N/A	<p><b>Folic Acid Supplementation for Hyperhomocysteinemia</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D and post-transplant who have hyperhomocysteinemia associated with kidney disease, we recommend not routinely supplementing folate with or without B-complex since there is no evidence demonstrating reduction in cardiovascular outcomes (1A).</li> </ul> <p><b>Folic Acid Deficiency and Insufficiency</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5 D (2B) and post-transplant (OPINION), we suggest prescribing folate, Vit B12 and/or B-complex supplement to correct for folate or Vitamin B12 deficiency/insufficiency (2B).</li> </ul>	New

63

63

Intervention Recommendations - Vitamins

KDOQI (2000)	KDOQI-AND (2019)	Changes
Vitamin C N/A	<p><b>Vitamin C Supplementation Limit</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5D and post-transplant who are at risk of Vitamin C deficiency it is reasonable to consider supplementation to meet the recommended intake of at least 90 mg/d for men and 75 mg/d for women (OPINION).</li> </ul>	New
Vitamin D N/A	<p><b>Anticoagulant Medication and Vitamin K Supplementation</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5D and post-transplant, it is reasonable that patients receiving anticoagulant medicines known to inhibit vitamin K activity (e.g., warfarin compounds) do not receive vitamin K supplements (OPINION).</li> </ul>	

64

64

Intervention Recommendations - Vitamins

KDOQI (2000)	KDOQI-AND (2019)	Changes
Vitamin E and A N/A	<p><b>Vitamins A and E Supplementation and Toxicity</b></p> <ul style="list-style-type: none"> <li>In adults with CKD on MHD or PD, it is reasonable to not routinely suggest vitamin A or E supplementation because of the potential for vitamin toxicity. However, if supplementation is warranted, it is reasonable to use caution and monitor patients for toxicity (OPINION).</li> </ul>	New

65

65

Intervention Recommendations - Vitamins

KDOQI (2000)	KDOQI-AND (2019)	Changes
Vitamin D N/A	<p><b>Vitamin D Supplementation for Vitamin D Deficiency and Insufficiency</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-5 D (2C) and post-transplant (OPINION), we suggest prescribing vitamin D supplementation in the form of cholecalciferol or ergocalciferol to correct 25(OH)D deficiency or insufficiency.</li> </ul> <p><b>Vitamin D Supplementation with Proteinuria</b></p> <ul style="list-style-type: none"> <li>In adults with CKD with chronic nephrotic range proteinuria, it is reasonable to consider supplementation of cholecalciferol, ergocalciferol or other safe and effective 25(OH)D precursors (OPINION).</li> </ul>	New

66

66

Intervention Recommendations - Acid Base Balance

KDOQI (2000)	KDOQI-AND (2019)	Changes
Measurement of Serum Bicarbonate	<p><b>Dietary Management of net acid production (NEAP)</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 1-4, we suggest reducing net acid production (NEAP) through increased dietary intake of fruits and vegetables (2C) in order to reduce the rate of decline of residual kidney function.</li> </ul>	Updated
Treatment of Low Serum Bicarbonate	<p><b>Bicarbonate Maintenance</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D, we suggest reducing net acid production (NEAP) through increased bicarbonate supplementation (1C) in order to reduce the rate of decline of residual kidney function.</li> <li>In adults with CKD 3-5D, it is reasonable to maintain serum bicarbonate levels at 24 - 26 mmol/L (OPINION).</li> </ul>	Updated

67

67

# Overview of the Nutrition in CKD Guidelines

## Slides

Intervention Recommendations - Electrolytes		
KDOQI (2000)	KDOQI-AND (2019)	Changes
Phosphorus N/A	<p><b>Dietary Phosphorus Amount</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5 and on MHD, we recommend adjusting dietary phosphorus intake to maintain serum phosphate levels in the normal range (1B).</li> </ul> <p><b>Dietary Phosphorus Source</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D and post-transplant, it is reasonable when making decisions about phosphorus restriction treatment to consider the bioavailability of phosphorus sources (e.g. animal, vegetable, additives) (OPINION).</li> </ul> <p><b>Phosphorus Intake with Hypophosphatemia</b></p> <ul style="list-style-type: none"> <li>For adult kidney transplant recipients with hypophosphatemia, it is reasonable to consider prescribing high-phosphorus intake (diet or supplements) in order to replete serum phosphorus (OPINION).</li> </ul>	New

68

Intervention Recommendations - Electrolytes		
KDOQI (2000)	KDOQI-AND (2019)	Changes
Calcium N/A	<p><b>Calcium Intake</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-4 not taking active vitamin D analogs, we suggest that a total elemental calcium intake of 800-1,000 mg/d (including dietary calcium, calcium supplementation and calcium-based phosphate binders) be prescribed to maintain a neutral calcium balance (2B).</li> </ul>	New

69

Intervention Recommendations - Electrolytes		
KDOQI (2000)	KDOQI-AND (2019)	Changes
Sodium N/A	<p><b>Sodium Intake and Blood Pressure</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5 (non-dialyzed) (1B), maintenance dialysis (1C), and post-transplant (1C), we recommend limiting sodium intake to less than 100 mmol/day (or &lt;2.3 g/day) to reduce blood pressure and improve volume control.</li> </ul> <p><b>Sodium Intake and Proteinuria</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5 (non-dialyzed), we suggest that reduced sodium intake 100 mmol/day (or &lt;2.3 g/day) be prescribed to reduce proteinuria (2A).</li> </ul> <p><b>Sodium Intake and Dry Body Weight</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D, we suggest reduced sodium intake as an adjunctive lifestyle modification strategy to achieve better volume control and a more desirable body weight (2B).</li> </ul>	New

70

Intervention Recommendations - Electrolytes		
KDOQI (2000)	KDOQI-AND (2019)	Changes
Potassium N/A	<p><b>Dietary Potassium Amount</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D and post-transplant, it is reasonable to adjust dietary potassium intake to maintain serum potassium within the normal range (OPINION).</li> </ul> <p><b>Dietary Potassium in Hyperkalemia</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5D and post-transplant who exhibit hyperkalemia, it is reasonable to consider lowering dietary potassium intake as a therapeutic strategy (OPINION).</li> </ul> <p><b>Potassium Intake for Hyperkalemia or Hypokalemia</b></p> <ul style="list-style-type: none"> <li>In adults with CKD 3-5 on MHD (2D) and post-transplant (OPINION) with either hyperkalemia or hypokalemia, we suggest that dietary or supplemental potassium intake be based on a patient's individual needs and clinician judgment.</li> </ul>	New

71

## Conclusion




72

## Thank you!


Laura Byham-Gray, PhD, RDN, FNKF  
 Denis Fouque, MD, PhD  
 Winnie Chan, PhD, RD  
 Jerrilyn Burrows, PhD, RD, CDN  
 Daniel Teta, MD, PhD  
 Angela Wang, MD, PhD  
 Jordi Fuchs, DSc, APN, NP-C, RD  
 Joel Kopple, MD  
 Sana Ghaddar, PhD, RDN  
 Juan Jesus Carrero, PhD Pharm, PhD Med, MBA  
 Katrina Campbell, PhD, RD  
 George Kayser, MD, PhD  
 Allison Friedman, MD, FASN  
 Lilian Cuppari, PhD

- National Kidney Foundation
- Academy of Nutrition and Dietetics
- Deepa Handu, PhD, RD, LDN
- Allison Steiber, PhD, RDN
- Mary Roza, PhD, RDN
- Kerr Willis, PhD
- Michael Rocco, MD
- Thomas Manley
- Deborah Taylor, MPH




73

## Slides



74